You are here
Efficacy and Safety for Primary Care Physicians
In this course you will learn about basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy, and how the efficacy and safety of this approach surpasses that of the individual components. The course will provide information on how to identify patients who are most likely to benefit from this combination. Practical considerations will be discussed, including tips on how to best manage patients during treatment with basal insulin–GLP-1 receptor agonist combination therapy.
Improved Efficacy Outcomes With Basal Insulin–GLP-1 Receptor Agonist Combinations in Patients With Type 2 Diabetes
In this animated e-learning module we discuss improved efficacy outcomes with basal insulin–GLP-1 receptor agonist combinations in patients with type 2 diabetes. The module was developed in collaboration with Professor Stephen Colagiuri, and focuses on four clinical trials of IDegLira and LixiLan (iGlarLixi).
• Lower risk of hypoglycaemia and less weight gain than insulin component
• Fewer gastrointestinal side effects than GLP-1 RA component
• Other adverse events
In this webcast, Professor Harris discusses the rationale for using basal insulin–GLP-1 RA combination therapy, and talks about the practical aspects of treating patients with fixed-dose combinations of basal insulin and a GLP-1 RA.